3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Esophageal Neoplasms
2
Vascular Complications
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immune Checkpoint Inhibitors
×
90 days
×
Clear all
No trials found.